Liability in the delivery of personalized medicine: driver, impediment, or both?
Liability in the delivery of personalized medicine: driver, impediment, or both?
批准号:
8707517
负责人:
GARY E. MARCHANT
金额:
$29.26万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2016-07-31
关键词:
AdoptedAdoptionAdvocateAffectAttentionBiological MarkersBusinessesCaringCase StudyClinicalCommunicationCosts and BenefitsDevelopmentDiagnostic testsEmpirical ResearchEnsureFutureGatekeepingGeneticHealthHealthcare SystemsIntellectual PropertyInterventionInvestigationLegalLegal LiabilityLitigationMedicalMedical TechnologyMedicineModelingNatureOutcomePatient CarePatientsPatternPharmaceutical PreparationsPhysiciansPlayPoliciesPolicy ResearchProceduresPublic HealthRampResearchResistanceRiskRoleSafetyShapesSpace MedicineSystemTechnologyTestingTrainingUncertaintyValidationbeneficiaryclinical carecourteconomic costhealth care deliveryimprovedinnovationoutreachoutreach programstandard of caresuccesstooltrenduptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Personalized medicine (PM) has the potential to transform medicine and the health care system over the next decade. An overlooked variable that will play an important role in the implementation of PM is the potential for legal liability. Physicians, a key gatekeeper in the uptake of PM, are at the greatest risk of liability. Currently,
there is great uncertainty, disagreement and rapid change with regard to the use of PM tests in clinical care. It is during this period of uncertainty and change where the potential for liabilityis at its greatest and thus the need for comprehensive legal research and analysis of the intersection of these issues is most pressing. This proposed project seeks to fill the gap in the understanding of PM liability risks by providing legal doctrinal, empirical, and policy research on
the risks, impacts and possible policy approaches with regard to PM liability. The results of this project can help to better understand and predict the future course of PM and to identify the key legal and policy levers that may be available to ensure that liability plays a beneficial rather thn detrimental role in the implementation of PM. This project has five primary objectives. This project will provide a comprehensive investigation and analysis of potential liability to physicians, first by examining the applicable claims, defenses and doctrines that will, provide the legal framework for liability, and which themselves are currently undergoing important changes. Second, we will evaluate the potential risks of liability to physicians by integrating the
doctrinal analysis with the fact patterns and evidence in four likely PM case studies, as well as by evaluating liability lessons from the uptake of previous medical technologies and practices. Third, we will examine the likely impact liability will have on physicians, patients, and the broader adoption, availability and implementation of PM. Fourth, we will identify and evaluate policy tools that can be used to better manage risks and uncertainties in the PM arena. Finally, we will communicate the findings and implications of our project through an outreach program targeting three key stakeholder groups: (i) physicians and medical educators; (ii) patient groups and advocates; and (iii) legal practitioners (including judges). At this critical juncture in the rollout of PM, before widespread liability has taken hold, it is very important and useful to comprehensively study and make widely available the best information and projections of the risks and relevant factors for physician liability relating to PM.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
DOI:
10.1586/14737159.2015.983476
发表时间:
2015-02
期刊:
Expert review of molecular diagnostics
影响因子:
5.1
作者:
[Issa AM, Chaudhari VS, Marchant GE]
通讯作者:
Marchant GE
DOI:
10.1177/1073110516644210
发表时间:
2016-03
期刊:
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics
影响因子:
--
作者:
[Marchant GE, Scheckel K, Campos-Outcalt D]
通讯作者:
Campos-Outcalt D
The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence.
癌症药物基因组学经济学研究的质量:证据的定量评估。
DOI:
10.1586/14737167.2013.838023
发表时间:
2013
期刊:
Expert review of pharmacoeconomics & outcomes research
影响因子:
2.3
作者:
[Yang,Mo, Patel,DhavalS, Tufail,Waqas, Issa,AmaliaM]
通讯作者:
Issa,AmaliaM
DOI:
10.1038/gim.2013.142
发表时间:
2013-12
期刊:
Genetics in medicine : official journal of the American College of Medical Genetics
影响因子:
--
作者:
[]
通讯作者:
Liability in the delivery of personalized medicine: driver, impediment, or both?
-
批准号:8292785
-
项目类别:
-
资助金额:$28.76万
-
财政年份:2012
-
负责人:GARY E. MARCHANT
-
依托单位:
Liability in the delivery of personalized medicine: driver, impediment, or both?
-
批准号:8519503
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2012
-
负责人:GARY E. MARCHANT
-
依托单位:
Genetic Susceptibility and Environmental Regulation
-
批准号:6746909
-
项目类别:
-
资助金额:$26.26万
-
财政年份:2003
-
负责人:GARY E. MARCHANT
-
依托单位:
Genetic Susceptibility and Environmental Regulation
-
批准号:6613613
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2003
-
负责人:GARY E. MARCHANT
-
依托单位:
海外基金